T1	PROC 44 125	Ensayo de 26 semanas, multicéntrico, aleatorizado, abierto, de 2 grupos paralelos
T2	CHEM 175 191	insulina detemir
#1	AnnotatorNotes T2	C0537270; insulin detemir; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T3	CHEM 204 241	insulina protamina neutra de Hagedorn
#2	AnnotatorNotes T3	C0021658; Neutral Protamine Hagedorn Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T4	CHEM 261 271	metformina
#3	AnnotatorNotes T4	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T5	PROC 296 313	control glucémico
#4	AnnotatorNotes T5	C3669205; Blood glucose monitoring; Therapeutic or Preventive Procedure | C5392125; Glycemic Control; Therapeutic or Preventive Procedure | C3267174; Glycaemia control; Therapeutic or Preventive Procedure
T6	DISO 342 360	diabetes de tipo 2
#5	AnnotatorNotes T6	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T7	PROC 280 289	ejercicio
#6	AnnotatorNotes T7	C0452240; Physical therapy exercises; Therapeutic or Preventive Procedure
T8	CHEM 394 404	metformina
#7	AnnotatorNotes T8	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T9	CHEM 413 427	antidiabéticos
#8	AnnotatorNotes T9	C0935929; Antidiabetics; Pharmacologic Substance
T10	CHEM 437 445	insulina
#9	AnnotatorNotes T10	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T11	DISO 474 489	Diabetes tipo 2
#10	AnnotatorNotes T11	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T12	DISO 515 539	Diabetes Mellitus tipo 2
#11	AnnotatorNotes T12	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T13	PROC 569 593	Consentimiento informado
#12	AnnotatorNotes T13	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T14	PROC 799 813	procedimientos
#13	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T15	PROC 1104 1115	Diagnóstico
#14	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 1119 1146	diabetes mellitus de tipo 2
#15	AnnotatorNotes T16	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T17	PROC 1198 1209	Tratamiento
#16	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	CHEM 1221 1231	metformina
#17	AnnotatorNotes T18	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T19	CHEM 1289 1297	insulina
#18	AnnotatorNotes T19	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T20	CHEM 1283 1286	ADO
#19	AnnotatorNotes T20	[antidiabéticos orales]
T21	DISO 1460 1502	Diabetes juvenil de comienzo en la madurez
#20	AnnotatorNotes T21	C0342276; Maturity onset diabetes mellitus in young; Disease or Syndrome
T22	DISO 1504 1508	MODY
#21	AnnotatorNotes T22	C0342276; Maturity onset diabetes mellitus in young; Disease or Syndrome
T23	CHEM 1514 1523	Péptido C
#22	AnnotatorNotes T23	C0006558; C-Peptide; Amino Acid, Peptide, or Protein · Biologically Active Substance
T24	PROC 1514 1533	Péptido C en ayunas
#23	AnnotatorNotes T24	C2208720; fasting C-peptide level; Laboratory Procedure
T25	DISO 1565 1584	Disfunción hepática
#24	AnnotatorNotes T25	C0086565; Liver Dysfunction; Finding
T26	CHEM 1612 1636	alanina aminotransferasa
#25	AnnotatorNotes T26	C0001899; Alanine Transaminase; Amino Acid, Peptide, or Protein · Enzyme
T27	PROC 1638 1641	ALT
#26	AnnotatorNotes T27	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T28	DISO 1695 1720	Retinopatía proliferativa
#27	AnnotatorNotes T28	C0339467; Proliferative retinopathy; Disease or Syndrome
T29	DISO 1723 1734	maculopatía
#28	AnnotatorNotes T29	C0730362; Disorder of macula of retina; Disease or Syndrome
T30	PROC 1762 1773	tratamiento
#29	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	PROC 131 168	investigar la eficacia y la seguridad
T32	PROC 274 279	dieta
#30	AnnotatorNotes T32	C0012159; Diet therapy; Health Care Activity | C0600072; Feeding and dietary regimes; Therapeutic or Preventive Procedure
T33	PROC 1062 1086	consentimiento informado
#31	AnnotatorNotes T33	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T34	PROC 1356 1361	HbA1c
#32	AnnotatorNotes T34	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T35	ANAT 1576 1584	hepática
#33	AnnotatorNotes T35	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T36	PROC 1603 1636	valor de alanina aminotransferasa
T37	Date 12 16	2013
T38	Duration 54 64	26 semanas
T39	LIVB 317 322	niños
#34	AnnotatorNotes T39	C0008059; Child; Age Group
T40	Route 428 434	orales
#35	AnnotatorNotes T40	C1527415; Oral Route of Drug administration; Functional Concept
T41	LIVB 598 606	paciente
#36	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	LIVB 612 631	representante legal
#37	AnnotatorNotes T42	C4288823; Legal Representative for the Study; Human
T43	LIVB 656 660	niño
#38	AnnotatorNotes T43	C0008059; Child; Age Group
T44	LIVB 950 957	Hombres
#39	AnnotatorNotes T44	C0025266; Male population group; Population Group
T45	LIVB 960 967	mujeres
#40	AnnotatorNotes T45	C0043210; Woman; Population Group
T46	Age 994 1016	entre los 10 y 17 años
T47	Duration 1155 1171	al menos 3 meses
T48	Dose 1233 1245	1000-2000 mg
T49	Frequency 1245 1249	/día
T50	Duration 1312 1328	al menos 3 meses
T53	LIVB 1802 1814	investigador
#41	AnnotatorNotes T53	C0035173; Research Personnel; Professional or Occupational Group
T54	LIVB 325 337	adolescentes
#42	AnnotatorNotes T54	C0205653; Adolescent (age group); Age Group
A1	Population_data T39 Age
A2	Population_data T54 Age
A3	Population_data T43 Age
A4	Status T29 History_of
A5	Status T28 History_of
#43	AnnotatorNotes T31	C0511730; Identify product efficacy and safety issues; Health Care Activity
#44	AnnotatorNotes T36	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T51	Result_or_Value 1643 1690	≥ 2,5 veces el límite superior de la normalidad
R1	Has_Result_or_Value Arg1:T27 Arg2:T51	
R2	Has_Result_or_Value Arg1:T36 Arg2:T51	
R3	Location_of Arg1:T35 Arg2:T25	
T52	Result_or_Value 1534 1544	<0,6 ng/ml
R6	Has_Result_or_Value Arg1:T24 Arg2:T52	
T55	Quantifier_or_Qualifier 1774 1779	agudo
R7	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T55	
R8	Has_Duration_or_Interval Arg1:T1 Arg2:T38	
R9	Combined_with Arg1:T3 Arg2:T4	
R10	Combined_with Arg1:T2 Arg2:T4	
R11	Combined_with Arg1:T4 Arg2:T32	
R13	Experiences Arg1:T39 Arg2:T2	
R14	Experiences Arg1:T54 Arg2:T2	
R15	Experiences Arg1:T39 Arg2:T3	
R16	Experiences Arg1:T54 Arg2:T3	
T56	Quantifier_or_Qualifier 361 389	insuficientemente controlada
R17	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T56	
R18	Has_Route_or_Mode Arg1:T9 Arg2:T40	
R19	Combined_with Arg1:T8 Arg2:T9	
R20	Combined_with Arg1:T9 Arg2:T10	
T57	Quantifier_or_Qualifier 446 451	basal
#45	AnnotatorNotes T57	C1442488; Baseline; Quantitative Concept
R21	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T57	
R22	Experiences Arg1:T39 Arg2:T5	
R23	Experiences Arg1:T54 Arg2:T5	
R24	Used_for Arg1:T2 Arg2:T5	
R25	Used_for Arg1:T3 Arg2:T5	
R26	Has_Age Arg1:T44 Arg2:T46	
R27	Has_Age Arg1:T45 Arg2:T46	
R28	Overlap Arg1:T33 Arg2:T46	
R29	Has_Duration_or_Interval Arg1:T16 Arg2:T47	
T58	PROC 1184 1193	selección
#46	AnnotatorNotes T58	C0242802; Patient Selection; Research Activity
R30	Before Arg1:T16 Arg2:T58	
R31	Before Arg1:T15 Arg2:T58	
R32	Used_for Arg1:T18 Arg2:T17	
T59	Quantifier_or_Qualifier 1210 1217	estable
R33	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T59	
R34	Has_Dose_or_Strength Arg1:T18 Arg2:T48	
R35	Has_Frequency Arg1:T18 Arg2:T49	
T60	Quantifier_or_Qualifier 1251 1255	sola
R36	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T60	
R37	Combined_with Arg1:T17 Arg2:T20	
R38	Combined_with Arg1:T17 Arg2:T19	
T61	Quantifier_or_Qualifier 1298 1303	basal
#47	AnnotatorNotes T61	C1442488; Baseline; Quantitative Concept
R39	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T61	
R40	Has_Duration_or_Interval Arg1:T18 Arg2:T50	
T62	PROC 1341 1350	selección
#48	AnnotatorNotes T62	C0242802; Patient Selection; Research Activity
R41	Before Arg1:T17 Arg2:T62	
T63	Result_or_Value 1362 1412	≥ 7,0 % y ≤ 10,5 % (≥ 53 mmol/mol y ≤ 91 mmol/mol)
R42	Has_Result_or_Value Arg1:T34 Arg2:T63	
#49	AnnotatorNotes T55	C0205178; acute; Temporal Concept
R43	Experiences Arg1:T54 Arg2:T6	
R44	Experiences Arg1:T39 Arg2:T6	
R45	Experiences Arg1:T39 Arg2:T8	
R46	Experiences Arg1:T54 Arg2:T8	
R47	Before Arg1:T8 Arg2:T2	
R48	Before Arg1:T8 Arg2:T3	
T64	PROC 1419 1428	selección
#50	AnnotatorNotes T64	C0242802; Patient Selection; Research Activity
R52	Overlap Arg1:T34 Arg2:T64	
T65	PROC 1551 1560	selección
#51	AnnotatorNotes T65	C0242802; Patient Selection; Research Activity
R53	Overlap Arg1:T24 Arg2:T65	
T66	PROC 728 734	ensayo
#52	AnnotatorNotes T66	C0008976; Clinical Trials; Research Activity
R54	Before Arg1:T13 Arg2:T66	
R55	Combined_with Arg1:T4 Arg2:T7	
T67	Observation 1087 1099	asentimiento
T68	Observation 639 651	asentimiento
R12	Experiences Arg1:T43 Arg2:T68	
R56	Overlap Arg1:T67 Arg2:T46	
R57	Experiences Arg1:T45 Arg2:T67	
R58	Experiences Arg1:T44 Arg2:T67	
R49	Before Arg1:T68 Arg2:T66	
#53	AnnotatorNotes T68	C1302239; Patient consented to clinical trial; Finding (?)
#54	AnnotatorNotes T67	C1302239; Patient consented to clinical trial; Finding (?)
#55	AnnotatorNotes T59	C0205360; Stabl status; Qualitative Concept
#56	AnnotatorNotes T60	C0205171; Singular; Quantitative Concept
A6	Experiencer T39 Patient
A7	Experiencer T54 Patient
A8	Experiencer T41 Patient
A9	Experiencer T42 Other
A10	Experiencer T43 Patient
A11	Experiencer T44 Patient
A12	Experiencer T45 Patient
A13	Experiencer T53 Other
